NO20085131L - Lyofiliserte preparater av anti-EGFR-antistoffer - Google Patents

Lyofiliserte preparater av anti-EGFR-antistoffer

Info

Publication number
NO20085131L
NO20085131L NO20085131A NO20085131A NO20085131L NO 20085131 L NO20085131 L NO 20085131L NO 20085131 A NO20085131 A NO 20085131A NO 20085131 A NO20085131 A NO 20085131A NO 20085131 L NO20085131 L NO 20085131L
Authority
NO
Norway
Prior art keywords
egfr antibodies
lyophilized preparations
lyophilized
stable
present
Prior art date
Application number
NO20085131A
Other languages
English (en)
Norwegian (no)
Inventor
Meera Agarkhed
Arvind Srivastava
Joel Goldstein
Original Assignee
Imclone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Systems Inc filed Critical Imclone Systems Inc
Publication of NO20085131L publication Critical patent/NO20085131L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO20085131A 2006-06-14 2008-12-09 Lyofiliserte preparater av anti-EGFR-antistoffer NO20085131L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81395806P 2006-06-14 2006-06-14
PCT/US2007/071119 WO2007147001A2 (en) 2006-06-14 2007-06-13 Lyophilized formulations of anti-egfr antibodies

Publications (1)

Publication Number Publication Date
NO20085131L true NO20085131L (no) 2009-03-13

Family

ID=38832820

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20085131A NO20085131L (no) 2006-06-14 2008-12-09 Lyofiliserte preparater av anti-EGFR-antistoffer

Country Status (18)

Country Link
US (1) US20100158925A1 (de)
EP (1) EP2029163A4 (de)
JP (1) JP2009540015A (de)
KR (1) KR20090021298A (de)
CN (1) CN101466404A (de)
AU (1) AU2007260769A1 (de)
BR (1) BRPI0713421A2 (de)
CA (1) CA2654794A1 (de)
CR (1) CR10493A (de)
EA (1) EA200870538A1 (de)
EC (1) ECSP088962A (de)
IL (1) IL195794A0 (de)
MA (1) MA30515B1 (de)
MX (1) MX2008015852A (de)
NO (1) NO20085131L (de)
TN (1) TNSN08511A1 (de)
WO (1) WO2007147001A2 (de)
ZA (1) ZA200810456B (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094247B1 (de) * 2006-10-20 2022-06-29 Amgen Inc. Stabile polypeptid-formulierungen
WO2009113083A1 (en) 2008-03-14 2009-09-17 Biocon Limited A monoclonal antibody and a method thereof
CN101716343A (zh) * 2008-10-09 2010-06-02 哈药集团生物工程有限公司 一种单克隆抗体的冻干制剂
FR2944448B1 (fr) * 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
EP2501408B1 (de) * 2009-11-20 2020-05-27 Biocon Limited Formulierungen aus antikörpern
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
BR112012013148A2 (pt) * 2009-12-29 2017-03-21 F Hoffmann - La Roche Ag formulação farmacêutica e uso
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP3409289B1 (de) 2010-02-26 2020-09-30 Novo Nordisk A/S Stabile, antikörperhaltige zusammensetzungen
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
RU2012153786A (ru) 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP3024485B1 (de) 2013-07-23 2020-11-18 Biocon Limited Verwendung eines cd6-bindungspartners und verfahren damit
CN105722859B (zh) * 2013-07-25 2021-05-07 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
CN104341505A (zh) * 2013-07-29 2015-02-11 西藏海思科药业集团股份有限公司 对蒙古人种和高加索人种低免疫原性的、抗egfr的人鼠嵌合抗体
JP6282745B2 (ja) * 2013-09-12 2018-02-21 ハロザイム インコーポレイテッド 修飾抗上皮成長因子受容体抗体およびその使用法
WO2015185998A2 (en) 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
TW201618774A (zh) 2014-08-11 2016-06-01 艾森塔製藥公司 使用ｂｔｋ抑制劑透過調變腫瘤微環境來治療實體腫瘤及其他疾病之方法
JP6214790B2 (ja) * 2014-09-16 2017-10-18 イース チャーム リミテッド 抗ｅｇｆｒ抗体および同抗体の使用法
CN112656939B (zh) * 2014-09-22 2023-12-08 正大天晴药业集团股份有限公司 一种针对血管内皮生长因子的人源化抗体的药物组合物
WO2016055982A1 (en) 2014-10-10 2016-04-14 Acerta Pharma B.V. Quinoline and quinazoline compounds
WO2016087994A1 (en) 2014-12-05 2016-06-09 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
CA3138083A1 (en) * 2014-12-22 2016-06-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
US12428483B2 (en) 2014-12-22 2025-09-30 Systimmune, Inc. Bispecific tetravalent antibodies and methods of making and using thereof
KR101776879B1 (ko) 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
US10736893B2 (en) 2015-11-06 2020-08-11 Acerta Pharma B.V. Imidazopyrazine inhibitors of Bruton's tyrosine kinase
ES2991182T3 (es) 2016-10-21 2024-12-02 Biocon Ltd Un anticuerpo monoclonal y un método de uso para el tratamiento del lupus
AU2017386888B2 (en) * 2016-12-28 2024-08-08 Jcr Pharmaceuticals Co., Ltd. Lyophilized preparation
US11639391B2 (en) * 2017-04-18 2023-05-02 Dr. Reddy's Laboratories Limited Stable liquid pharmaceutical composition
EP3694885A1 (de) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antikörper, aktivierbare antikörper, bispezifische antikörper und bispezifische aktivierbare antikörper und verfahren zur verwendung davon
SG11202011538RA (en) * 2018-06-01 2020-12-30 Rakuten Medical Inc Phthalocyanine dye conjugate compositions
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
MA54861A (fr) 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
JP2022535924A (ja) * 2019-06-06 2022-08-10 ジャナックス セラピューティクス，インク． 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
EP4631977A3 (de) 2020-08-11 2025-12-10 Janux Therapeutics, Inc. Spaltbare linkerzusammensetzungen und verfahren
AU2021396172A1 (en) 2020-12-09 2023-07-06 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
US20240383968A1 (en) * 2020-12-11 2024-11-21 Boehringer Ingelheim International Gmbh Formulation for multi-purpose application
JP2024536275A (ja) * 2021-10-03 2024-10-04 システィミューン， インク． がんを治療する方法及びその医薬組成物
CN119855620A (zh) * 2022-09-16 2025-04-18 国立研究开发法人量子科学技术研究开发机构 放射性医药组合物的中间体的制造方法、放射性医药组合物的中间体的纯化用试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62158160A (ja) * 1985-12-27 1987-07-14 堺化学工業株式会社 成形触媒及び接触反応方法
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6695940B2 (en) * 2001-04-05 2004-02-24 Alan D. Devoe Laminate thin-wall ceramic tubes, including with integral stress wrappings, thickened ends and/or internal baffles, particularly for solid oxide fuel cells
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
CA2560305C (en) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
CN101495136A (zh) * 2006-02-15 2009-07-29 英克隆系统公司 抗体配制品

Also Published As

Publication number Publication date
ZA200810456B (en) 2009-12-30
CA2654794A1 (en) 2007-12-21
AU2007260769A1 (en) 2007-12-21
WO2007147001A3 (en) 2008-07-10
BRPI0713421A2 (pt) 2012-03-13
MA30515B1 (fr) 2009-06-01
WO2007147001A2 (en) 2007-12-21
KR20090021298A (ko) 2009-03-02
EP2029163A4 (de) 2010-08-11
EA200870538A1 (ru) 2009-04-28
IL195794A0 (en) 2011-08-01
US20100158925A1 (en) 2010-06-24
TNSN08511A1 (en) 2010-04-14
JP2009540015A (ja) 2009-11-19
EP2029163A2 (de) 2009-03-04
ECSP088962A (es) 2009-01-30
CN101466404A (zh) 2009-06-24
CR10493A (es) 2009-02-26
MX2008015852A (es) 2009-02-23

Similar Documents

Publication Publication Date Title
NO20085131L (no) Lyofiliserte preparater av anti-EGFR-antistoffer
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
MY169272A (en) Her2 antibody composition
NZ719036A (en) Anti-pdl1 antibody formulations
EA201270625A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
MX343087B (es) Aislamiento y purificacion de anticuerpos usando la cromatografia de afinidad de proteina a.
EA201400933A1 (ru) Агенты, связывающие склеростин
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
ATE517922T1 (de) Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
AR092216A1 (es) Formulaciones estables de anticuerpos contra tslp
BRPI0514340A (pt) formulações de estabilização
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
NO20080612L (no) Immunokonjugatpreparater
NO20064413L (no) Multikomponent biologiske transportsystemer
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MY174493A (en) Binding agents
EA200870264A1 (ru) Композиция антител
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
WO2006086561A3 (en) Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
BRPI0921261A2 (pt) anticorpos que se ligam imunoespecificamente a peptídeos igf-1 humanos modificados , hibridoma, polipeptídeo isolado, ácido nucleico que codifica um anticorpo, vetor compreendendo um ácido nucléico, célula hospedeira compreendendo um vetor, ensaio imunosorvente ligado a enzima aperfeiçoado (elisa), método de manter uma dose ótima de igf-1/e modificada, método cromatográfico de afinidade aperfeiçoado e uso de igf-1/e modificado.
EA202190382A1 (ru) Фармацевтические составы на основе маскированных антител
PT1105503E (pt) Guanililciclase humana soluvel alfal/betal (hsgc alfal/betal) isolada e purificada
WO2007023189A3 (en) Pharmaceutical composition and its use for the prophylactic or therapeutic treatment of retroviral diseases

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO

FC2A Withdrawal, rejection or dismissal of laid open patent application